HealthPharmaceuticalsObesity TreatmentGlobal
Drugmakers race to find a place in the next wave of obesity drugs
Drugmakers are developing a new generation of obesity treatments beyond today's leading GLP-1 medications.
Executive Summary
Drugmakers are intensifying efforts to enter the rapidly expanding obesity treatment market currently dominated by Eli Lilly and Novo Nordisk. Companies including Pfizer, AstraZeneca, Amgen, Structure Therapeutics and Zealand Pharma are pursuing oral pills, monthly injections and entirely new mechanisms beyond GLP-1 therapies, while Lilly continues to advance next-generation candidates such as retatrutide and eloralintide.
Key Takeaways
- ✓Eli Lilly and Novo Nordisk currently dominate the obesity drug market.
- ✓Drugmakers are developing pills, monthly injections and new mechanisms beyond GLP-1.
- ✓Retatrutide produced average weight loss of 28 percent in Phase 3 studies.
- ✓Amylin-based drugs are emerging as a potential new class of obesity medicines.
- ✓Pfizer and Amgen are exploring less frequent dosing schedules.
- ✓Around 890 million people worldwide are classified as obese.
- ✓Pricing and insurance coverage are expected to shape future competition.
- ✓Experts believe obesity treatment will become increasingly personalized.
#Eli Lilly#Novo Nordisk#Pfizer#Amgen#AstraZeneca#Structure Therapeutics#Zealand Pharma#GLP-1#Weight Loss#Diabetes#Healthcare
